Platelet glycoprotein Ib alpha chain (GPIbα) (GPIbα)

Platelet glycoprotein Ib alpha (GPIbα) is the primary ligand-binding subunit of the GPIb-IX-V complex, a major adhesion receptor on the platelet surface (UniProt: P07359). The interaction between the GPIbα N-terminal domain and the A1 domain of von Willebrand factor (vWF) is uniquely specialized to initiate platelet tethering and rolling under high-shear stress conditions, such as those found in narrowed arteries (PubMed: 11912091). This interaction is a prerequisite for subsequent firm adhesion and thrombus formation mediated by other receptors like integrin αIIbβ3. In pathological states, such as thrombotic thrombocytopenic purpura (TTP), ultra-large vWF multimers spontaneously bind to GPIbα, leading to microvascular thrombosis (PubMed: 30625066). Therapeutic targeting of this axis, exemplified by the nanobody caplacizumab, aims to block the vWF A1-GPIbα interaction to prevent thrombosis while potentially sparing normal hemostasis in low-shear environments (PubMed: 29653964). Other experimental agents, such as the snake venom-derived anfibatide, directly target GPIbα to inhibit this adhesion pathway (PubMed: 25605816). This target is clinically significant because it offers a potentially wider therapeutic window with reduced bleeding risk compared to traditional antiplatelet agents like aspirin or P2Y12 inhibitors.

Other names

GP1BACD42bGlycoprotein Ib alphaCD42b-alphaBDPLT2BSS

Inhibition of the interaction between the platelet glycoprotein Ib alpha receptor and the von Willebrand factor A1 domain, thereby preventing shear-dependent platelet adhesion and thrombus formation.